Gilead Sciences (NASDAQ:GILD) Stock Price Up 1.7%

Gilead Sciences, Inc. (NASDAQ:GILD)’s stock price shot up 1.7% on Tuesday . The stock traded as high as $72.05 and last traded at $71.98. 1,104,589 shares were traded during trading, a decline of 85% from the average session volume of 7,451,861 shares. The stock had previously closed at $70.81.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research report on Wednesday, April 24th. TD Cowen cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Maxim Group reduced their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Finally, Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a report on Monday, July 8th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $84.00.

Gilead Sciences Trading Up 1.2 %

The company has a market capitalization of $89.25 billion, a P/E ratio of 199.94, a PEG ratio of 3.00 and a beta of 0.18. The business has a 50 day moving average price of $66.53 and a 200 day moving average price of $71.61. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period last year, the business posted $1.37 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 3.71 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.30%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC increased its position in Gilead Sciences by 3.4% during the second quarter. V Square Quantitative Management LLC now owns 26,728 shares of the biopharmaceutical company’s stock worth $1,834,000 after buying an additional 891 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after acquiring an additional 33,162 shares during the last quarter. NorthCrest Asset Manangement LLC raised its stake in Gilead Sciences by 1.2% in the 2nd quarter. NorthCrest Asset Manangement LLC now owns 114,323 shares of the biopharmaceutical company’s stock valued at $7,844,000 after acquiring an additional 1,372 shares during the period. Diversified Trust Co boosted its position in Gilead Sciences by 11.8% during the second quarter. Diversified Trust Co now owns 32,987 shares of the biopharmaceutical company’s stock worth $2,263,000 after purchasing an additional 3,483 shares during the period. Finally, Gemmer Asset Management LLC acquired a new position in shares of Gilead Sciences in the second quarter valued at $270,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.